Application 018902

Type
NDA
Sponsor
FRESENIUS KABI USA

Related Records

Application Products

ProductDrugIngredientFormStrengthReference drugReference standard
001FUROSEMIDEFUROSEMIDEINJECTABLE;INJECTION10MG/MLNoNo

NDC Listings For This Application

NDCNameNonproprietary nameLabelerMarketing categoryStatus
51662-1572FUROSEMIDEFUROSEMIDEHF Acquisition Co LLC, DBA HealthFirstNDACurrent
51662-1572FUROSEMIDEFUROSEMIDEHF Acquisition Co LLC, DBA HealthFirstNDACurrent
51662-1574FUROSEMIDEFUROSEMIDEHF Acquisition Co LLC, DBA HealthFirstNDACurrent
51662-1574FUROSEMIDEFUROSEMIDEHF Acquisition Co LLC, DBA HealthFirstNDACurrent
51662-1574FUROSEMIDEFUROSEMIDEHF Acquisition Co LLC, DBA HealthFirstNDACurrent
51662-1574FUROSEMIDEFUROSEMIDEHF Acquisition Co LLC, DBA HealthFirstNDACurrent
51662-1575FUROSEMIDEFUROSEMIDEHF Acquisition Co LLC, DBA HealthFirstNDACurrent
55154-9581FurosemideFUROSEMIDECardinal Health 107, LLCNDACurrent
55154-9581FurosemideFUROSEMIDECardinal HealthNDACurrent
55154-9582FurosemideFUROSEMIDECardinal HealthNDACurrent
55154-9582FurosemideFUROSEMIDECardinal Health 107, LLCNDACurrent
63323-280FurosemideFUROSEMIDEFresenius Kabi USA, LLCNDACurrent
63323-280FurosemideFUROSEMIDEFresenius Kabi USA, LLCNDACurrent
63323-280FurosemideFUROSEMIDEFresenius Kabi USA, LLCNDACurrent
63323-280FurosemideFUROSEMIDEFresenius Kabi USA, LLCNDACurrent
63323-280FurosemideFUROSEMIDEFresenius Kabi USA, LLCNDACurrent
81565-201FurosemideFUROSEMIDEPhlow CorporationNDACurrent

Documents

DocumentSubmission typeDate
79815SUPPL 2024-10-03
79808SUPPL 2024-10-03
73606SUPPL 2023-02-24
73602SUPPL 2023-02-24
70766SUPPL2022-04-14
70757SUPPL2022-04-13
45353SUPPL2016-09-21
33640SUPPL2016-03-14
16087SUPPL2016-03-10